Arcadia Biosciences Receives US Patent for Extended Shelf Life Wheat Trait Designed to Increase Whole Grain Consumption and Minimize Waste

— Newest technology expands company’s GoodWheatTM portfolio of high-value, functional wheat ingredients —

DAVIS, Calif. (October 15, 2018)Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural food ingredient company, today announced that the United States Patent and Trademark Office has granted the company a patent for extended shelf life wheat, the newest trait in Arcadia’s non-genetically modified (non-GM) GoodWheatTM portfolio.

US Patent No. 10,087,455, entitled “Wheat With Reduced Lipoxygenase Activity,” covers this new technology which extends the storage life of whole wheat flour by minimizing oxidation. This new trait was designed to promote whole wheat consumption by improving the shelf life and taste of whole grain wheat products.

“This patent demonstrates our commitment to developing exciting innovations for consumers and food companies to drive the adoption of whole wheat,” said Raj Ketkar, president and CEO of Arcadia. “Commercial plans are underway, and we look forward to sharing those soon.”

The issuance of this key US patent further expands Arcadia’s global patent portfolio, which includes more than 195 patents and patent applications owned or exclusively controlled by Arcadia.

About Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. Arcadia’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company’s agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. For more information, visit

Note Regarding Forward-Looking Statements . This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia’s and its partners’ and affiliates’ ability to develop commercial products incorporating their traits and complete the regulatory review process for such products; Arcadia’s compliance with laws and regulations that impact Arcadia’s business; Arcadia’s ability to enter into favorable commercial relationships; Arcadia’s future capital requirements and ability to satisfy its capital needs; Arcadia’s ability to develop, secure, enforce and defend its intellectual property rights; and the other risks set forth in Arcadia’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2017 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.